Handelsavisen
prelaunch
Companies ›Healthcare ›ELVN.O
EL
ELVN.O — NASDAQ Pharmaceuticals

Enliven Therapeutics Inc

$58,44
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
3,5B USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-22,6 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Enliven Therapeutics Inc is a pharmaceutical company operating in the Health Care sector, focused on drug development within the Pharmaceuticals industry.

Business. Enliven Therapeutics Inc (ELVN.O) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY12 analysts
12 buy0 hold0 sell
Avg 12m price target65,80

Analyst recommendations

12 analysts · consensus Buy
Buy12
Hold0
Sell0
12-month price target
65,80
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
12 analysts · indicative
Ownership→
FMR LLC
largest disclosed fund holder
Profitability→
-22,6 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ELVN.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ELVN.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Enliven Therapeutics Inc (ELVN.O) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification85 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    Enliven Therapeutics maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet shows total assets of $476.2 million against total liabilities of $16.6 million, leaving total equity at $459.6 million. Liquidity is supported by cash and equivalents of $98.9 million, though operating cash flow is negative at -$70.3 million, indicating ongoing cash burn typical of pre-revenue or early-stage biopharma firms. The current ratio is not explicitly provided, but the high cash position relative to low liabilities suggests adequate short-term solvency despite the negative operating cash flow.

    Profitability metrics reflect the company's development stage, with a net income of -$103.7 million and an operating income of -$119.7 million. Return on equity is -22.56% and return on assets is -21.78%, consistent with a firm investing heavily in R&D without yet generating significant revenue. The price-to-book ratio stands at 6.82, implying the market values the company's intangible assets and pipeline potential significantly above its tangible book value. EV/EBITDA is negative at -25.37, further highlighting the lack of current earnings.

    Key takeaways
    • Enliven Therapeutics operates with a debt-free balance sheet and $98.9 million in cash, providing a buffer against its -$70.3 million operating cash flow.
    • The company is unprofitable with a net loss of $103.7 million, resulting in negative ROE (-22.56%) and ROA (-21.78%).
    • Analysts are bullish, with a mean price target of $65.80 (24.8% upside) and a strong buy consensus (1.58 rating).
    • Valuation multiples are high (P/B 6.82) and earnings-based multiples are negative, reflecting the speculative nature of the pre-profitability stage.
    • No segment or geographic revenue data is available, limiting the ability to assess market concentration risks.
    • Risk assessment flags are low for both liquidity and dilution, suggesting stable capital structure management in the near term.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-07
    Q1 2026 · Quarter highlights
    Open report →

    Operating income +12,2% YoY; Net income +17,2% YoY.

    Revenue—
    Operating income-$27.8M+12,2 % YoY
    Net income-$23.6M+17,2 % YoY
    Free cash flow-$23.6M+17,1 % YoY
    EPS—
    Operating cash flow-$19.3M+20,0 % YoY
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income-$27.8M
    Net income-$23.6M
    Balance sheet
    Total assets$464.9M
    Total liabilities$11.5M
    Total equity$453.4M
    Cash & equivalents$132.2M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$19.3M
    CapEx$0.00
    Free cash flow-$23.6M
    SBC—
    Highlights
    • ▍Operating income +12,2% YoY
    • ▍Net income +17,2% YoY
    • ▍Free cash flow +17,1% YoY

    Valuation TTM

    Market price
    $58,44
    Market cap
    $3.13B
    Enterprise valueⓘ
    $3.04B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    6.8x
    P / Tangible bookⓘ
    6.8x
    Tangible book
    $459.6M
    Net cashⓘ
    $98.9M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    -21.8%
    ROEⓘ
    -22.6%
    Cash conversionⓘ
    68.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 36 %
    EPS
    Consensus EPS
    -1,75
    Predicted surprise
    -0,02
    Beat probability
    36 %
    Analysts
    12
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-07-28 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-1,75
    Revenue—no estimate—no estimate0 USD
    Operating income—no estimate—no estimate-132,1M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution12 analysts
    Strong buy5
    Buy7
    Hold0
    Sell0
    Strong sell0
    12-month price target$65,80 · Median $63,50
    Low $55,00High $80,00
    Operating income · consensus-132,1M USD
    EPS surprise
    −4,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$55,00
    Mean$65,80
    Median$63,50
    High$80,00
    Spot$58,44
    +12.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-22,6 %Bottom quartile
    D/E0,00Above P75
    Cash Conv0,68Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 500 144 sh11 exercises · 12 grants11 insiders
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 5 000 @ $2,48exercise · 2026-07-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Stock Option (right to buy) → Common StockDisposed 1 072 @ $2,48exercise · 2026-07-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Stock Option (right to buy) → Common StockDisposed 6 018 @ $2,48exercise · 2026-06-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 5 000 @ $2,48exercise · 2026-06-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 5 000 @ $2,48exercise · 2026-05-18
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 5 000 @ $2,48exercise · 2026-04-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 40 000 @ $2,48exercise · 2026-03-25
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 5 000 @ $2,48exercise · 2026-03-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 10 129 @ $2,48exercise · 2026-03-10
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 29 871 @ $2,48exercise · 2026-03-09
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockDisposed 45 000 @ $2,48exercise · 2026-02-17
    • Bauer JakeDirector · Stock Option (right to buy) → Common StockAcquired 17 126 @ $27,16grant · 2026-02-12
    • Ballal Rahul D.Director · Stock Option (right to buy) → Common StockAcquired 17 126 @ $27,16grant · 2026-02-12
    • Patel AnishCHIEF OPERATING OFFICER · Stock Option (right to buy) → Common StockAcquired 120 000 @ $27,16grant · 2026-02-12
    • Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · Stock Option (right to buy) → Common StockAcquired 112 500 @ $27,16grant · 2026-02-12
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Stock Option (right to buy) → Common StockAcquired 150 000 @ $27,16grant · 2026-02-12
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockAcquired 150 000 @ $27,16grant · 2026-02-12
    • Garland J. ScottDirector · Stock Option (right to buy) → Common StockAcquired 1 427 @ $27,16grant · 2026-02-12
    • Derynck Mika KDirector · Stock Option (right to buy) → Common StockAcquired 17 126 @ $27,16grant · 2026-02-12
    • Gupta RishiDirector · Stock Option (right to buy) → Common StockAcquired 1 580 @ $27,16grant · 2026-02-12
    • Gupta RishiDirector · Stock Option (right to buy) → Common StockAcquired 33 989 @ $27,16grant · 2026-02-12
    • Heyman Richard A.Director · Stock Option (right to buy) → Common StockAcquired 19 234 @ $27,16grant · 2026-02-12
    • Kunkel Lori AnneDirector · Stock Option (right to buy) → Common StockAcquired 17 126 @ $27,16grant · 2026-02-12

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Enliven Therapeutics, Inc. Market data — financials · 2026-07-28
    • reconciler_enqueue (reconciler) on ELVN.O · 2026-07-28
    • Enliven Therapeutics Inc Market data — analyst estimates · 2026-07-28
    • Enliven Therapeutics Inc Market data — ESG · 2026-07-28

    Ownership & reference

    Top holders

    • FMR LLCInstitutional Investor · as of 2026-03-310,01 %$268M
    • Jennison Associates LLCInvestment Managers · as of 2026-03-310,01 %$12M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,01 %$27M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$12M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$42M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$19M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$14M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$11M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$15M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$43M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$6M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$64M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$20M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$6M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$5M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$2M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$43M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$2M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Richard HeymanExecutive Chairman of the Board

    Insider activity

    Net selling0 buys · 41 sellsnet -$58,4M7 insiders · last 365d
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockSold 2 184 @ $53,42$117K · 2026-07-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockOther 1 072 @ $2,48$3K · 2026-07-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockSold 324 @ $49,97$16K · 2026-07-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockSold 369 @ $51,48$19K · 2026-07-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockSold 2 564 @ $52,32$134K · 2026-07-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockSold 2 638 @ $53,38$141K · 2026-07-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockSold 123 @ $53,87$7K · 2026-07-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockOther 5 000 @ $2,48$12K · 2026-07-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockSold 231 @ $50,05$12K · 2026-07-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockSold 459 @ $51,55$24K · 2026-07-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockSold 2 063 @ $52,39$108K · 2026-07-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockSold 63 @ $53,92$3K · 2026-07-17
    • Kunkel Lori AnneDirector · Common StockSold 4 111 @ $49,98$205K · 2026-07-06
    • Kunkel Lori AnneDirector · Common StockSold 5 889 @ $50,84$299K · 2026-07-06
    • ORBIMED ADVISORS LLC10% owner · Common StockSold 46 776 @ $45,00$2,1M · 2026-06-22
    • ORBIMED ADVISORS LLC10% owner · Common StockSold 24 846 @ $45,38$1,1M · 2026-06-22
    • ORBIMED ADVISORS LLC10% owner · Common StockSold 1 477 @ $45,00$66K · 2026-06-22
    • ORBIMED ADVISORS LLC10% owner · Common StockSold 787 024 @ $45,38$35,7M · 2026-06-22
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockSold 1 133 @ $44,74$51K · 2026-06-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockSold 1 268 @ $42,83$54K · 2026-06-17
    • Collins Helen LouiseCHIEF MEDICAL OFFICER · Common StockSold 2 599 @ $43,87$114K · 2026-06-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockOther 6 018 @ $2,48$15K · 2026-06-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockSold 1 379 @ $42,78$59K · 2026-06-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockSold 3 401 @ $43,86$149K · 2026-06-17
    • Hohl BenjaminCHIEF FINANCIAL OFFICER · Common StockSold 1 238 @ $44,75$55K · 2026-06-17

    Short positioning

    8.7Mshares short+1.5% vs prior
    9.41days to cover
    35.1%short of daily vol
    402fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ELVN.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob36 %Surprise-0,02Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Shares outstanding (annual): 59.44MUnknown
    • Total assets (annual): USD 476.17MUnknown
    • R&D expense (annual): USD 85.86MUnknown
    • Total liabilities (annual): USD 16.57MUnknown
    • Total operating expenses (annual): USD 119.66MUnknown
    • Current assets (annual): USD 474.88MUnknown
    • Net income (annual): USD -103.7MUnknown
    • Current liabilities (annual): USD 16.57MUnknown
    • Operating income (annual): USD -119.66MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -2Unknown
    • Shareholders' equity (annual): USD 459.6MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -2Unknown
    • Operating cash flow (annual): USD -70.3MUnknown
    • Cash & equivalents (annual): USD 98.9MUnknown
    • Total operating expenses (annual): USD 104.55MUnknown
    • Current assets (annual): USD 318.13MUnknown
    • Operating income (annual): USD -104.55MUnknown
    • Cash & equivalents (annual): USD 124.12MUnknown
    • Total liabilities (annual): USD 15.91MUnknown
    • Total assets (annual): USD 325.76MUnknown
    • Shareholders' equity (annual): USD 309.85MUnknown
    • Current liabilities (annual): USD 15.91MUnknown
    • Operating cash flow (annual): USD -73.19MUnknown
    • R&D expense (annual): USD 80.78MUnknown
    Showing 24 of 26 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-17INSIDERCollins Helen Louise sold 63 sh — CHIEF MEDICAL OFFICER ~$3k
    2026-07-17INSIDERHohl Benjamin transacted 1.1k sh — CHIEF FINANCIAL OFFICER ~$3k
    2026-07-17INSIDERHohl Benjamin sold 324 sh — CHIEF FINANCIAL OFFICER ~$16k
    2026-07-17INSIDERHohl Benjamin sold 369 sh — CHIEF FINANCIAL OFFICER ~$19k
    2026-07-17INSIDERHohl Benjamin sold 2.6k sh — CHIEF FINANCIAL OFFICER ~$134k
    2026-07-17INSIDERHohl Benjamin sold 2.6k sh — CHIEF FINANCIAL OFFICER ~$141k
    2026-07-17INSIDERHohl Benjamin sold 123 sh — CHIEF FINANCIAL OFFICER ~$7k
    2026-07-17INSIDERCollins Helen Louise transacted 5.0k sh — CHIEF MEDICAL OFFICER ~$12k
    2026-07-17INSIDERCollins Helen Louise sold 231 sh — CHIEF MEDICAL OFFICER ~$12k
    2026-07-17INSIDERCollins Helen Louise sold 459 sh — CHIEF MEDICAL OFFICER ~$24k
    2026-07-17INSIDERCollins Helen Louise sold 2.1k sh — CHIEF MEDICAL OFFICER ~$108k
    2026-07-17INSIDERCollins Helen Louise sold 2.2k sh — CHIEF MEDICAL OFFICER ~$117k
    2026-07-17INSIDERHohl Benjamin disposed of 1.1k sh Stock Option (right to buy) — CHIEF FINANCIAL OFFICER
    2026-07-17INSIDERCollins Helen Louise disposed of 5.0k sh Stock Option (right to buy) — CHIEF MEDICAL OFFICER
    2026-07-06INSIDERKunkel Lori Anne sold 4.1k sh — Director ~$205k
    2026-07-06INSIDERKunkel Lori Anne sold 5.9k sh — Director ~$299k
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-22 00:00 UTCINSIDER19 insider transactions — 2026-06 · net sell $52.5M 2 derivative
    2026-06-22 00:00 UTCINSIDER19 insider transactions — 2026-06 · net sell $52.5M 2 derivative
    2026-06-22INSIDERORBIMED ADVISORS LLC sold 46.8k sh — 10% owner ~$2.10M
    2026-06-22INSIDERORBIMED ADVISORS LLC sold 24.8k sh — 10% owner ~$1.13M
    2026-06-22INSIDERORBIMED ADVISORS LLC sold 1.5k sh — 10% owner ~$66k
    2026-06-22INSIDERORBIMED ADVISORS LLC sold 787.0k sh — 10% owner ~$35.72M
    2026-06-17INSIDERCollins Helen Louise sold 1.1k sh — CHIEF MEDICAL OFFICER ~$51k
    2026-06-17INSIDERCollins Helen Louise sold 1.3k sh — CHIEF MEDICAL OFFICER ~$54k
    2026-06-17INSIDERCollins Helen Louise sold 2.6k sh — CHIEF MEDICAL OFFICER ~$114k
    2026-06-17INSIDERHohl Benjamin transacted 6.0k sh — CHIEF FINANCIAL OFFICER ~$15k
    2026-06-17INSIDERHohl Benjamin sold 1.4k sh — CHIEF FINANCIAL OFFICER ~$59k
    2026-06-17INSIDERHohl Benjamin sold 3.4k sh — CHIEF FINANCIAL OFFICER ~$149k
    2026-06-17INSIDERHohl Benjamin sold 1.2k sh — CHIEF FINANCIAL OFFICER ~$55k
    2026-06-17INSIDERHohl Benjamin disposed of 6.0k sh Stock Option (right to buy) — CHIEF FINANCIAL OFFICER
    2026-06-17INSIDERCollins Helen Louise disposed of 5.0k sh Stock Option (right to buy) — CHIEF MEDICAL OFFICER
    2026-06-12FILING8-K filing →
    2026-06-12FILING424B5 filing →
    2026-06-11FILING424B5 filing →
    2026-06-11FILING8-K filing →
    2026-06-10FILING8-K filing →
    2026-05-18 00:00 UTCINSIDER5 insider transactions — 2026-05 · net sell $187k 1 derivative
    2026-05-18 00:00 UTCINSIDER5 insider transactions — 2026-05 · net sell $187k 1 derivative
    Showing the 40 most recent of 74 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage